VANCOUVER, Canda I January 30, 2012 I biOasis Technologies Inc. (TSX-V: BTI.V – News) announced today that work is underway at Texas Tech University Health Sciences Center (TTUHSC) to perform a series of preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin®) in animal models of breast cancer metastasis in the brain. The studies at TTUHSC will be conducted under the direction of Drs. Quentin Smith and Paul Lockman – both recognized experts in the blood-brain barrier and in evaluating drug delivery to the central nervous system for the treatment of brain tumors.
This program being conducted with TTUHSC follows on the results generated at the British Columbia Cancer Research Center showing that BT2111 had better in vitro cancer killing activity than Herceptin® alone and from animal studies conducted at the National Research Council (Ottawa) and the iCapture Centre (Vancouver), demonstrating a 10-fold increase in BT2111 transport into the brain compared with Herceptin® alone.
BT2111 is a conjugate between biOasis’s Transcend brain delivery vector p97 and trastuzumab (trade name of Herceptin®), a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier, biOasis is researching the potential of BT2111 for treatment of HER2+ metastatic breast cancer in the brain.
Herceptin® is a registered trademark of Genentech.
ABOUT BIOASIS
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more information about the Company please visit www.bioasis.ca.
SOURCE: bioOasis
Post Views: 56
VANCOUVER, Canda I January 30, 2012 I biOasis Technologies Inc. (TSX-V: BTI.V – News) announced today that work is underway at Texas Tech University Health Sciences Center (TTUHSC) to perform a series of preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin®) in animal models of breast cancer metastasis in the brain. The studies at TTUHSC will be conducted under the direction of Drs. Quentin Smith and Paul Lockman – both recognized experts in the blood-brain barrier and in evaluating drug delivery to the central nervous system for the treatment of brain tumors.
This program being conducted with TTUHSC follows on the results generated at the British Columbia Cancer Research Center showing that BT2111 had better in vitro cancer killing activity than Herceptin® alone and from animal studies conducted at the National Research Council (Ottawa) and the iCapture Centre (Vancouver), demonstrating a 10-fold increase in BT2111 transport into the brain compared with Herceptin® alone.
BT2111 is a conjugate between biOasis’s Transcend brain delivery vector p97 and trastuzumab (trade name of Herceptin®), a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier, biOasis is researching the potential of BT2111 for treatment of HER2+ metastatic breast cancer in the brain.
Herceptin® is a registered trademark of Genentech.
ABOUT BIOASIS
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more information about the Company please visit www.bioasis.ca.
SOURCE: bioOasis
Post Views: 56
